InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Poly(I:C) (HMW) VacciGrade™ | Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delive... | 2022 | Pharm Res. | Ji A. et al. | DOI: 10.1007/s11095-022-03445-1 |
| IFA | IFNGR/STAT1 signaling in recipient hematopoietic antigen presenting cells sup... | 2022 | J Clin Invest. | Lu C. et al. | DOI: 10.1172/JCI125986 |
| EndoFit™ OVA protein | IFNGR/STAT1 signaling in recipient hematopoietic antigen presenting cells sup... | 2022 | J Clin Invest. | Lu C. et al. | DOI: 10.1172/JCI125986 |
| Blasticidin | Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 an... | 2022 | Int J Pharm. | Noverraz F. et al. | DOI: 10.1016/j.ijpharm.2022.122463 |
| SARS-CoV-2 Spike expressing HEK293 cells | Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 an... | 2022 | Int J Pharm. | Noverraz F. et al. | DOI: 10.1016/j.ijpharm.2022.122463 |
| Normocin® - Antimicrobial Reagent | Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 an... | 2022 | Int J Pharm. | Noverraz F. et al. | DOI: 10.1016/j.ijpharm.2022.122463 |
| G418 (Geneticin) | Rationally designed antifungal protein chimeras reveal new insights into stru... | 2022 | Int J Biol Macromol. | Giner-Llorca M. et al. | DOI: 10.1016/j.ijbiomac.2022.11.280 |
| Pam3CSK4 | Pim1 promotes IFN-β production by interacting with IRF3. | 2022 | Exp Mol Med. | Ko R. et al. | DOI: 10.1038/s12276-022-00893-y |
| HEK-Blue™ Detection | Biallelic TLR4 deficiency in humans. | 2022 | J Allergy Clin Immunol. | Capitani M. et al. | DOI: 10.1016/j.jaci.2022.08.030 |
| Hygromycin B Gold | Biallelic TLR4 deficiency in humans. | 2022 | J Allergy Clin Immunol. | Capitani M. et al. | DOI: 10.1016/j.jaci.2022.08.030 |
| Human MD2 and CD14 Reporter HEK293 Cells (NF-κB) | Biallelic TLR4 deficiency in humans. | 2022 | J Allergy Clin Immunol. | Capitani M. et al. | DOI: 10.1016/j.jaci.2022.08.030 |
| Zeocin® | Biallelic TLR4 deficiency in humans. | 2022 | J Allergy Clin Immunol. | Capitani M. et al. | DOI: 10.1016/j.jaci.2022.08.030 |
| CL075 (3M002) | Comparison of the immunomodulatory potential of platinum-based anti-cancer dr... | 2022 | Cancer Chemother Pharmacol. | Jenei V. et al. | DOI: 10.1007/s00280-022-04497-1 |
| Jurkat Reporter Cells (NFAT) | Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitme... | 2022 | J Immunother Cancer | Cyr M.G. et al. | DOI: 10.1136/jitc-2022-004850 |
| QUANTI-Luc™: Luciferase Detection Reagent | Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitme... | 2022 | J Immunother Cancer | Cyr M.G. et al. | DOI: 10.1136/jitc-2022-004850 |
| THP1-Lucia™ ISG Cells | Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. | 2022 | PNAS | Wu Y.T. et al. | DOI: 10.1073/pnas.2214278119 |
| LumiKine™ Xpress mIFN-β 2.0 | Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. | 2022 | PNAS | Wu Y.T. et al. | DOI: 10.1073/pnas.2214278119 |
| RAW-Lucia™ ISG Cells | Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. | 2022 | PNAS | Wu Y.T. et al. | DOI: 10.1073/pnas.2214278119 |
| Nucleocapsid (N) Expression Vector | Two formulations of coronavirus disease-19 recombinant subunit vaccine candid... | 2022 | Immun Inflamm Dis. | Özcengiz E. et al. | DOI: 10.1002/iid3.748 |
| CR3022-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes | Two formulations of coronavirus disease-19 recombinant subunit vaccine candid... | 2022 | Immun Inflamm Dis. | Özcengiz E. et al. | DOI: 10.1002/iid3.748 |